CY1118089T1 - Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης - Google Patents

Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης

Info

Publication number
CY1118089T1
CY1118089T1 CY20161100972T CY161100972T CY1118089T1 CY 1118089 T1 CY1118089 T1 CY 1118089T1 CY 20161100972 T CY20161100972 T CY 20161100972T CY 161100972 T CY161100972 T CY 161100972T CY 1118089 T1 CY1118089 T1 CY 1118089T1
Authority
CY
Cyprus
Prior art keywords
disposal
crystal
liquid composition
substances
compound liquid
Prior art date
Application number
CY20161100972T
Other languages
English (en)
Inventor
Freixedas Félix Grases
Bestard Joan Perello
Espinosa Fernando Tur
Bauza Antonia Costa
Almirall Rafael M Prieto
Muñiz Isabel Gomila
Original Assignee
Universitat De Les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat De Les Illes Balears filed Critical Universitat De Les Illes Balears
Publication of CY1118089T1 publication Critical patent/CY1118089T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μία σύνθεση η οποία περιλαμβάνει φωσφορικές και/ή διφωσφονικές ινοσιτόλες και τη χρήση αυτών εις την πρόληψη της απώλειας ουσιών βιολογικής σημασίας εις τον οργανισμό ασθενών οι οποίοι υποβάλλονται σε διαπίδυση και τη διατήρηση φυσιολογικών επιπέδων των εν λόγω ουσιών, επαρκών ώστε να ρυθμίζουν φυσιολογικές και/ή παθολογικές διαδικασίες, όπου οι ουσίες είναι ανασταλτικές της παθολογικής κρυστάλλωσης.
CY20161100972T 2008-08-06 2016-09-30 Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης CY1118089T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200802363A ES2332636B1 (es) 2008-08-06 2008-08-06 Composicion de liquido de dialisis.
PCT/ES2009/070156 WO2010018278A2 (es) 2008-08-06 2009-05-14 Composición que comprende sustancias inhibidoras de la cristalización

Publications (1)

Publication Number Publication Date
CY1118089T1 true CY1118089T1 (el) 2017-06-28

Family

ID=41058532

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100972T CY1118089T1 (el) 2008-08-06 2016-09-30 Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης
CY20201100395T CY1122973T1 (el) 2008-08-06 2020-04-29 Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100395T CY1122973T1 (el) 2008-08-06 2020-04-29 Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης

Country Status (20)

Country Link
US (4) US8778912B2 (el)
EP (2) EP3103456B1 (el)
JP (4) JP2011529759A (el)
CN (2) CN104224809A (el)
AU (1) AU2009281096B2 (el)
BR (1) BRPI0911938A2 (el)
CA (2) CA2975801C (el)
CY (2) CY1118089T1 (el)
DK (2) DK2324835T3 (el)
ES (3) ES2332636B1 (el)
HK (1) HK1203843A1 (el)
HR (2) HRP20161170T1 (el)
HU (2) HUE031173T2 (el)
LT (2) LT2324835T (el)
MX (1) MX2011001278A (el)
PL (2) PL3103456T3 (el)
PT (2) PT3103456T (el)
RU (2) RU2535094C2 (el)
SI (2) SI2324835T1 (el)
WO (1) WO2010018278A2 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US9364490B2 (en) * 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
DE102014013885A1 (de) 2014-09-18 2016-03-24 Fresenius Medical Care Deutschland Gmbh Dialyselösung
JP7007716B2 (ja) * 2015-06-04 2022-01-25 アモーフィカル リミテッド． ポリリン酸塩又はビスホスホネートで安定化した非晶質炭酸カルシウム
DE102015007842A1 (de) * 2015-06-18 2016-12-22 Fresenius Medical Care Deutschland Gmbh Dialyselösung
CN113788855B (zh) * 2015-12-11 2024-03-01 苏黎世联邦理工学院 用于病理性结晶的肌醇衍生物
US11028112B2 (en) 2015-12-11 2021-06-08 Eth Zurich Inositol derivatives for use in pathological crystallization
US11707470B2 (en) 2015-12-11 2023-07-25 Eth Zurich Inositol derivatives for use in pathological crystallization
CN107550992B (zh) * 2017-08-16 2018-05-25 安徽天康(集团)股份有限公司 一种治疗痛风的药物及其制备方法
BR112021006004A2 (pt) 2018-10-11 2021-06-29 Sanifit Therapeutics S.A. inositol fosfatos para o tratamento de calcificações ectópicas.
CN113365636A (zh) 2019-01-30 2021-09-07 萨尼菲特治疗有限公司 用于增加组织灌注的磷酸肌醇化合物
EP3965775A4 (en) * 2019-05-10 2023-05-10 Fresenius Medical Care Deutschland GmbH COMPOSITION AND CONCENTRATE FOR USE IN THE PREPARATION OF A DIALYSIS SOLUTION, CORRESPONDING DIALYSIS SOLUTION AND COMBINATIONS COMPRISING A CONTAINER
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
WO2024023360A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip5 substituted compounds
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
JP4143118B2 (ja) * 1993-02-23 2008-09-03 ブリガム・アンド・ウイミンズ・ホスピタル・インコーポレイテッド カルシウム受容体活性化分子およびその関連物
JPH1149671A (ja) * 1997-08-06 1999-02-23 Baxter Internatl Inc 腹膜透析液
RU2126973C1 (ru) * 1997-10-07 1999-02-27 Слюсарь Николай Николаевич Способ коррекции нарушений фосфоинозитидного обмена
EG24303A (en) * 1998-10-20 2009-01-12 Advanced Renal Technologies Buffered compositions for dialysis
DE19912850B4 (de) * 1999-03-22 2005-04-07 Fresenius Medical Care Deutschland Gmbh Lösung, insbesondere für Hämo- oder Peritonealdialyse, sowie Verfahren zu deren Herstellung
DE29910454U1 (de) * 1999-06-10 1999-09-23 Vitasyn Gmbh Mittel zur Therapie von Hyperphosphatämie
EP1223985B1 (en) * 1999-10-15 2005-11-30 Dow Global Technologies Inc. Dialysis solution including polyglycol osmotic agent
JP2002249433A (ja) * 2000-12-19 2002-09-06 Sumitomo Pharmaceut Co Ltd 血管石灰化抑制剤
JP2003238414A (ja) * 2001-12-13 2003-08-27 Sangaku Renkei Kiko Kyushu:Kk 医薬組成物
KR101249707B1 (ko) * 2003-10-28 2013-04-05 에모리 유니버시티 투석액 및 이에 관련된 방법과 시스템
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
ES2288126B2 (es) * 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.

Also Published As

Publication number Publication date
EP3103456B1 (en) 2020-02-12
JP5978251B2 (ja) 2016-08-24
EP2324835B1 (en) 2016-07-20
ES2785566T3 (es) 2020-10-07
ES2332636A1 (es) 2010-02-09
PL2324835T3 (pl) 2017-01-31
WO2010018278A2 (es) 2010-02-18
JP2014210782A (ja) 2014-11-13
HRP20200733T1 (hr) 2020-10-16
US20150374752A1 (en) 2015-12-31
CN104224809A (zh) 2014-12-24
US8778912B2 (en) 2014-07-15
ES2332636B1 (es) 2011-02-10
LT2324835T (lt) 2016-10-10
BRPI0911938A2 (pt) 2015-10-20
SI2324835T1 (sl) 2017-01-31
HUE049269T2 (hu) 2020-09-28
CA2975801A1 (en) 2010-02-18
US9155750B2 (en) 2015-10-13
RU2011115356A (ru) 2012-10-27
LT3103456T (lt) 2020-05-11
CA2732881A1 (en) 2010-02-18
AU2009281096B2 (en) 2016-07-21
JP2016183196A (ja) 2016-10-20
EP2324835A2 (en) 2011-05-25
CA2975801C (en) 2018-08-07
JP6412068B2 (ja) 2018-10-24
US20110172194A1 (en) 2011-07-14
RU2535094C2 (ru) 2014-12-10
SI3103456T1 (sl) 2020-09-30
PT2324835T (pt) 2016-10-25
DK3103456T3 (da) 2020-05-04
HK1203843A1 (en) 2015-11-06
DK2324835T3 (en) 2016-11-14
JP6799041B2 (ja) 2020-12-09
PL3103456T3 (pl) 2020-09-21
EP3103456A1 (en) 2016-12-14
US20170119799A1 (en) 2017-05-04
HRP20161170T1 (hr) 2016-11-04
CY1122973T1 (el) 2021-10-29
MX2011001278A (es) 2011-05-30
US20140302166A1 (en) 2014-10-09
WO2010018278A3 (es) 2010-12-16
CA2732881C (en) 2017-09-26
AU2009281096A1 (en) 2010-02-18
RU2691060C2 (ru) 2019-06-10
JP2011529759A (ja) 2011-12-15
PT3103456T (pt) 2020-05-06
CN102143754A (zh) 2011-08-03
ES2595227T3 (es) 2016-12-28
HUE031173T2 (en) 2017-07-28
RU2014127746A (ru) 2016-01-27
JP2019019134A (ja) 2019-02-07

Similar Documents

Publication Publication Date Title
CY1118089T1 (el) Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
DE502007006879D1 (de) Resorbierbares calciumphosphatbasierendes biopolymervernetztes knochenersatzmaterial
UY32123A (es) Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones
CO6270257A2 (es) Derivados de piridazinona
ATE402663T1 (de) Flächiges implantat
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
ATE390925T1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
UY32030A (es) "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
DE602005019247D1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
CY1121465T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια της φλεγμονωδους νοσου του εντερου
CL2008002368A1 (es) Uso de gaboxadol para preparar un medicamento util en el tratamiento de la depresion en pacientes que tienen uno o mas marcadores inflamatorios elevados o anormales.
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα
DK1889920T3 (da) In vitro fremgangsmåde atil identifikation af forbindelse atil cancerterapi
CY1114735T1 (el) Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5
CY1116802T1 (el) Ετεροκυκλικες ενωσεις
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs